Pierelli L, Teofili L, Menichella G, et al: Further investiga- tions on the expression of HLA-DR, CD33 and CD13 surface anti- gens in purified bone marrow and peripheral blood CD34' hemato- poietic progenitor cells. Br J Haematol 84:24-30, 1994...
Fourteen CD33 binding agents (fully human monoclonal antibodies as listed in table 1 as No. 1-14, respectively) to human and cynomolgus CD33 were determined by FACS Scatchard analysis as described in Brockhoff et al., (Cytometry. 1994 Sep. 1; 17(1):75-83) on CD33 expressing cells (AML-...
Immature myeloid cells (HLA-DR−/lowCD33+CD16−) were tested before and after granulocyte colony-stimulating factor (G-CSF) administration in healthy donor and isolated for suppression assays and co-culture with T cells in vitro. Isolated cells were infused in humanized mice for a xenogeneic ...
Further investigations on the expression of HLA-DR, CD33 and CD13 surface antigens in purified bone marrow and peripheral blood CD34+ haematopoietic progenitor cells. Br J Haematol, 84 (1993), p. 24 CrossrefView in ScopusGoogle Scholar 17 B Dorken, G Moldenhauer, A Pezzutto, R Schwartz, ...
11 7.5 12/M MDS/AML Monosomy 7 PIF CR1 10/10 MUD No No/2.9 26 DR 100 Grade II Yes Aliveday +589 12 7.5 1/F AML-M4 None PIF CR1 5/6 UCB Yes No/1.0 35 76 99 Grade II No Deadday + 473 M indicates male; F, female; HLA, human leukocyte antigen; A, alive; D, dead; RI...
5.当向癌症患者施用抗cd33癌症疗法时,该疗法可以以“在靶(on-target)、非白血病”效果不仅消耗cd33+癌细胞,还消耗非癌性cd33+细胞。由于造血干细胞(hsc)和造血祖细胞(hpc)通常表达cd33,故非癌性cd33+细胞的损失消耗患者的造血系统。为了解决该消耗,可以向受试者施用在cd33基因中包含修饰的拯救细胞(例如,hsc和/...